BOPAL’s updates

Following the publication of a new post on our blog, this week we would like to announce that BOPAL is conducting an important study in Chile that involves an inhaled vaccine for COVID-19 as a booster dose in the pediatric and adolescent population, from CanSino Biologics. Inc.

 

This inhaled vaccine has recently been approved for emergency use as a booster vaccine in China, becoming the first country in the world to approve a needle-free inhaled version of a COVID-19 vaccine.

See international press release:(https://www.reuters.com/world/china/cansinos-inhaled-covid-19-vaccine-gets-emergency-use-approval-china-2022-09-04/)

 

This vaccine is a new version of CanSino’s one-shot COVID-19 drug, the first in the world to undergo human testing in March 2020 and which has been used in China, Mexico, Chile, Argentina, Pakistan, Malaysia and Hungary after being rolled out in February 2021. The inhaled version can stimulate cellular immunity and induce mucosal immunity to boost protection without intramuscular injection.

 

At BOPAL we are very happy to participate in innovative projects that can generate a benefit for the population and as a CRO we will keep promoting the innovation and quality to contribute and make clinical research in Chile and Latin America growth.

 

To discuss planning your clinical trial in Chile, please contact at pablo@bopal.cl